Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jinyouli for Neutropenia Prevention in NHL
NCT04497688Unknown
- Sponsor
- CSPC Baike Biopharmaceutical
- Start
- Jan 2019
- Primary completion
- Sep 2020
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 1
01
Overview
Open-label, single-arm trial of pegylated granulocyte colony-stimulating factor in chemotherapy-induced neutropenia (CIN), sponsored by CSPC Baike Biopharmaceutical. Primary endpoint: The incidence of grade III/IV neutropenia up to 24 weeks. Status: unknown.
02
Drugs
pegylated granulocyte colony-stimulating factor
03
Conditions
chemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on NCT04497688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04497688.